Medprin Regenerative Medical Stock Cash Flow From Operations
| 301033 Stock | 44.99 0.72 1.58% |
Medprin Regenerative Medical fundamentals help investors to digest information that contributes to Medprin Regenerative's financial success or failures. It also enables traders to predict the movement of Medprin Stock. The fundamental analysis module provides a way to measure Medprin Regenerative's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medprin Regenerative stock.
Medprin | Cash Flow From Operations |
Medprin Regenerative Medical Company Cash Flow From Operations Analysis
Medprin Regenerative's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Medprin Regenerative Cash Flow From Operations | 107.69 M |
Most of Medprin Regenerative's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medprin Regenerative Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Medprin Regenerative Medical has 107.69 M in Cash Flow From Operations. This is 79.58% lower than that of the Health Care Equipment & Supplies sector and 70.53% lower than that of the Health Care industry. The cash flow from operations for all China stocks is 88.91% higher than that of the company.
Medprin Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medprin Regenerative's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medprin Regenerative could also be used in its relative valuation, which is a method of valuing Medprin Regenerative by comparing valuation metrics of similar companies.Medprin Regenerative is currently under evaluation in cash flow from operations category among its peers.
Medprin Fundamentals
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0633 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | 0.39 % | ||||
| Current Valuation | 2.86 B | ||||
| Shares Outstanding | 66.52 M | ||||
| Shares Owned By Insiders | 53.01 % | ||||
| Shares Owned By Institutions | 15.83 % | ||||
| Price To Book | 4.58 X | ||||
| Price To Sales | 10.84 X | ||||
| Revenue | 230.87 M | ||||
| Gross Profit | 220.53 M | ||||
| EBITDA | 107.26 M | ||||
| Net Income | 40.88 M | ||||
| Total Debt | 151.11 M | ||||
| Book Value Per Share | 10.09 X | ||||
| Cash Flow From Operations | 107.69 M | ||||
| Earnings Per Share | 1.04 X | ||||
| Number Of Employees | 278 | ||||
| Beta | -0.13 | ||||
| Market Capitalization | 2.99 B | ||||
| Total Asset | 786.97 M | ||||
| Retained Earnings | 114.02 M | ||||
| Working Capital | 201.59 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 786.97 M | ||||
| Last Dividend Paid | 0.4 |
About Medprin Regenerative Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medprin Regenerative Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medprin Regenerative using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medprin Regenerative Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Medprin Stock
Medprin Regenerative financial ratios help investors to determine whether Medprin Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medprin with respect to the benefits of owning Medprin Regenerative security.